Dr Reddy's Labs

{
  "main_header": {
    "sid": 734514,
    "name": "Dr Reddy's Labs",
    "stock_name": "Dr Reddy's Labs",
    "full_name": "Dr Reddys Laboratories Ltd",
    "name_url": "stocks-analysis/dr-reddy-s-labs",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 1,
    "country_id": 34,
    "currency": "INR",
    "cmp": "1,171.10",
    "chg": -0.95,
    "chgp": "-0.08%",
    "dir": -1,
    "prev_price": "1,172.05",
    "mcapval": "100,166.00 Cr",
    "mcap": "Mid Cap",
    "scripcode": "500124",
    "symbol": "DRREDDY",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "sector_id": 65,
    "indexname": "India SENSEX",
    "isin": "INE089A01031",
    "curr_date": "Sep 18, 03:30 PM",
    "curr_time": "01:27 AM",
    "last_traded_at": "Sep 18, 03:30 PM IST",
    "bse_nse_vol": "31.3 lacs",
    "exc_status": "Active",
    "traded_date": "Sep 18, 2026",
    "traded_date_str": "2026 09 18",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-registerF-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/dr-reddy-s-labs-734514-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "P/E at 30.36 vs Industry's 36.93: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-nifty-50-membership-amid-institutional-shifts-4196913",
        "imagepath": "",
        "date": "2026-09-18 09:20:45",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands at 30.36, which is approximately 17.8% below the Pharmaceuticals & Biotechnology industry average of 36.93. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives higher risks relative to its peers. The sector’s elevated P/E reflects optimism about growth prospects, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades with a valuation that may indicate a more conservative stance. Investors might wo..."
      },
      {
        "title": "P/E at 29.67 vs Industry's 36.44: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-challenges-amid-nifty-50-membership-4195878",
        "imagepath": "",
        "date": "2026-09-17 09:20:59",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry Average</strong></p>\n                <p>The current P/E ratio of 29.67 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> represents a discount of approximately 18.5% relative to the sector’s average of 36.44. This valuation gap suggests that the market is pricing in either a subdued growth outlook or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations driven by innovation and patent portfolios, this discount is analytically significant. It raises the question of whether the stock’s lower valuation is justified by fundamentals or if it presents a valuation anomaly — <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-..."
      },
      {
        "title": "P/E at 29.78 vs Industry's 36.52: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-nifty-50-membership-significance-4194618",
        "imagepath": "",
        "date": "2026-09-16 09:20:48",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discounted P/E Amid Sector Premiums</strong></p>\n                <p><a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> currently trades at a P/E of 29.78, which is approximately 18.5% below the Pharmaceuticals & Biotechnology industry average of 36.52. This discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Given the sector’s generally elevated valuations, the stock’s lower P/E could reflect concerns about recent earnings momentum or broader sector headwinds. The valuation gap invites the question <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"ctx\">previously rated Hold, what is Dr Reddy..."
      },
      {
        "title": "P/E at 30.07 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-sell-grade-amid-mixed-performance-and-institutional-shifts-4192877",
        "imagepath": "",
        "date": "2026-09-15 09:20:51",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands at 30.07, which is approximately 18.8% lower than the Pharmaceuticals & Biotechnology industry average of 37.05. This discount suggests that the market is pricing in either a relative undervaluation or concerns about the company’s near-term earnings growth compared to its peers. Given the sector’s elevated valuation, this gap is significant and invites scrutiny of the underlying fundamentals and market sentiment. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a>’s mid-cap status ..."
      },
      {
        "title": "P/E at 29.55 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-nifty-50-membership-significance-4189983",
        "imagepath": "",
        "date": "2026-09-11 09:20:55",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry Average</strong></p>\n                <p>The current P/E ratio of 29.55 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> represents a discount of approximately 20.3% relative to the sector’s average of 37.05. This valuation gap suggests the market is pricing in either subdued growth prospects or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations due to steady earnings and innovation potential, this discount merits closer scrutiny. <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a>’s mid-cap status with a market capitalisation of ₹95,099.26 crores pla..."
      },
      {
        "title": "P/E at 29.61 vs Industry's 37.21: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-challenges-amidst-nifty-50-membership-4188805",
        "imagepath": "",
        "date": "2026-09-10 09:20:46",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amid Sector Premiums</strong></p>\n                <p>The current P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> at 29.61 stands well below the industry average of 37.21, indicating the stock is trading at a 20% discount relative to its sector peers. This valuation gap suggests the market is pricing in either near-term challenges or a more cautious outlook compared to the broader Pharmaceuticals & Biotechnology sector. The sector’s elevated P/E reflects investor willingness to pay a premium for growth and innovation, but <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> appears to be viewed mo..."
      },
      {
        "title": "P/E at 29.83 vs Industry's 37.46: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-faces-downgrade-amidst-volatile-trading-and-benchmark-challenges-4187504",
        "imagepath": "",
        "date": "2026-09-09 09:25:45",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount to Industry Average</strong></p>\n                <p>The current P/E ratio of 29.83 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> represents a discount of approximately 20.4% relative to the sector average of 37.46. This valuation gap suggests the market is pricing in either subdued growth expectations or heightened risk factors compared to peers. Such a discount is significant in a sector where premium valuations often reflect strong pipeline prospects or robust earnings visibility. The stock’s mid-cap market capitalisation of ₹95,888.03 crores places it among sizeable players, yet the valuation gap raises questions about its comparative earnings quality or growth trajec..."
      },
      {
        "title": "Dr Reddys Laboratories Ltd is Rated Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/dr-reddys-laboratories-ltd-is-rated-sell-4186566",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/9/DrReddysLaborat_mojoScore_4186566.png",
        "date": "2026-09-08 10:10:03",
        "description": "Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with the latest insights into the company’s performance and outlook."
      },
      {
        "title": "P/E at 29.66 vs Industry's 37.22: What the Data Shows for Dr Reddys Laboratories Ltd",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/dr-reddys-laboratories-ltd-navigating-challenges-as-a-nifty-50-mid-cap-pharmaceutical-stock-4186074",
        "imagepath": "",
        "date": "2026-09-08 09:20:53",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n                <p><strong>Valuation Picture: Discount Amidst Sector Premiums</strong></p>\n                <p>The current P/E ratio of 29.66 for <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> stands well below the sector average of 37.22, indicating a valuation discount of roughly 20%. This gap suggests the market is pricing in either a relative weakness in earnings growth prospects or heightened risk factors compared to peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to its growth potential and defensive characteristics, yet <a href=\"https://www.marketsmojo.com/stocks-analysis/dr-reddy's-labs-734514-0\" class=\"stk\">Dr Reddys Laboratories Ltd</a> trades at a more conservative multiple. <a cl..."
      }
    ],
    "total": 673,
    "sid": "734514",
    "stock_news_url": "https://www.marketsmojo.com/news/dr-reddys-laboratories-734514"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "16-Sep-2026",
      "details": "Copies of newspaper publication",
      "source": "BSE"
    },
    {
      "caption": "Disclosure Under Regulation 30 Of SEBI (LODR) Regulations 2015",
      "datetime": "11-Sep-2026",
      "details": "Disclosure under Regulation 30 of SEBI (LODR) Regulations 2015",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation",
      "datetime": "10-Sep-2026",
      "details": "Intimation of Analyst meet",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has declared <strong>800%</strong> dividend, ex-date: 10 Jul 26",
          "dt": "2026-07-10",
          "middle_text": "Dividend Alert"
        }
      ]
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:5</strong> stock split, ex-date: 28 Oct 24",
          "dt": "2024-10-28",
          "middle_text": "Split"
        }
      ]
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "",
      "data": [
        {
          "txt": "Dr Reddys Laboratories Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 28 Aug 06",
          "dt": "2006-08-28",
          "middle_text": "Bonus Alert"
        }
      ]
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

P/E at 30.36 vs Industry's 36.93: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-18 09:20:45

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 30.36, which is approximately 17.8% below the Pharmaceuticals & Biotechnology industry average of 36.93. This discount suggests that the market is pricing in either a more cautious outlook on the company’s earnings growth or perceives higher risks relative to its peers. The sector’s elevated P/E reflects optimism about growth prospects, yet Dr Reddys Laboratories Ltd trades with a valuation that may indicate a more conservative stance. Investors might wo...

Read full news article

P/E at 29.67 vs Industry's 36.44: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-17 09:20:59

Valuation Picture: Discount to Industry Average

The current P/E ratio of 29.67 for Dr Reddys Laboratories Ltd represents a discount of approximately 18.5% relative to the sector’s average of 36.44. This valuation gap suggests that the market is pricing in either a subdued growth outlook or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations driven by innovation and patent portfolios, this discount is analytically significant. It raises the question of whether the stock’s lower valuation is justified by fundamentals or if it presents a valuation anomaly — Read full news article

P/E at 29.78 vs Industry's 36.52: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-16 09:20:48

Valuation Picture: Discounted P/E Amid Sector Premiums

Dr Reddys Laboratories Ltd currently trades at a P/E of 29.78, which is approximately 18.5% below the Pharmaceuticals & Biotechnology industry average of 36.52. This discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Given the sector’s generally elevated valuations, the stock’s lower P/E could reflect concerns about recent earnings momentum or broader sector headwinds. The valuation gap invites the question previously rated Hold, what is Dr Reddy...

Read full news article

P/E at 30.07 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-15 09:20:51

Valuation Picture: Discount Amidst Sector Premiums

The current P/E of Dr Reddys Laboratories Ltd stands at 30.07, which is approximately 18.8% lower than the Pharmaceuticals & Biotechnology industry average of 37.05. This discount suggests that the market is pricing in either a relative undervaluation or concerns about the company’s near-term earnings growth compared to its peers. Given the sector’s elevated valuation, this gap is significant and invites scrutiny of the underlying fundamentals and market sentiment. Dr Reddys Laboratories Ltd’s mid-cap status ...

Read full news article

P/E at 29.55 vs Industry's 37.05: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-11 09:20:55

Valuation Picture: Discount to Industry Average

The current P/E ratio of 29.55 for Dr Reddys Laboratories Ltd represents a discount of approximately 20.3% relative to the sector’s average of 37.05. This valuation gap suggests the market is pricing in either subdued growth prospects or elevated risks compared to peers. Given the pharmaceutical sector’s typical premium valuations due to steady earnings and innovation potential, this discount merits closer scrutiny. Dr Reddys Laboratories Ltd’s mid-cap status with a market capitalisation of ₹95,099.26 crores pla...

Read full news article

P/E at 29.61 vs Industry's 37.21: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-10 09:20:46

Valuation Picture: Discount Amid Sector Premiums

The current P/E ratio of Dr Reddys Laboratories Ltd at 29.61 stands well below the industry average of 37.21, indicating the stock is trading at a 20% discount relative to its sector peers. This valuation gap suggests the market is pricing in either near-term challenges or a more cautious outlook compared to the broader Pharmaceuticals & Biotechnology sector. The sector’s elevated P/E reflects investor willingness to pay a premium for growth and innovation, but Dr Reddys Laboratories Ltd appears to be viewed mo...

Read full news article

P/E at 29.83 vs Industry's 37.46: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-09 09:25:45

Valuation Picture: Discount to Industry Average

The current P/E ratio of 29.83 for Dr Reddys Laboratories Ltd represents a discount of approximately 20.4% relative to the sector average of 37.46. This valuation gap suggests the market is pricing in either subdued growth expectations or heightened risk factors compared to peers. Such a discount is significant in a sector where premium valuations often reflect strong pipeline prospects or robust earnings visibility. The stock’s mid-cap market capitalisation of ₹95,888.03 crores places it among sizeable players, yet the valuation gap raises questions about its comparative earnings quality or growth trajec...

Read full news article

Dr Reddys Laboratories Ltd is Rated Sell

2026-09-08 10:10:03

Dr Reddys Laboratories Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 13 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 September 2026, providing investors with the latest insights into the company’s performance and outlook.

Read full news article

P/E at 29.66 vs Industry's 37.22: What the Data Shows for Dr Reddys Laboratories Ltd

2026-09-08 09:20:53

Valuation Picture: Discount Amidst Sector Premiums

The current P/E ratio of 29.66 for Dr Reddys Laboratories Ltd stands well below the sector average of 37.22, indicating a valuation discount of roughly 20%. This gap suggests the market is pricing in either a relative weakness in earnings growth prospects or heightened risk factors compared to peers. The Pharmaceuticals & Biotechnology sector often commands premium valuations due to its growth potential and defensive characteristics, yet Dr Reddys Laboratories Ltd trades at a more conservative multiple. Read full news article

View All News